It was studied whether blocking several points of the angiogenesis pathway by adding sorafenib (a multikinase inhibitor of VEGFR-2/3 and PDGFR) to bevacizumab, would show clinical activity in ovarian cancer. The gene discussed is KDR; the disease is ovarian cancer.